制药工业在开发蛋白酶抑制剂治疗爱滋病领域方面已获得了一定的进展。1993年6月7日至11日在柏林举办的第9届国际爱滋病大会上,5家公司介绍了4个新化合物的研究进展。这4个新化合物是杜邦默克公司的DM—323、(XM—323)、汽巴—嘉基公司的CGP—53437、默克公司的 L—735524和拜尔公司与赫斯特公司联合研制的 Hoe/Bay—793,其中,DM—323正在进行Ⅰ期临床试验,L—735524也已接近临床试验阶段。此外,目前 The pharmaceutical industry has made some progress in the development of protease inhibitors for the treatment of AIDS. At the 9th International AIDS Conference held in Berlin from June 7 to 11, 1993, five companies introduced the research progress of four new compounds. The four new compounds are the DM-323 from DuPont Merck, (XM-323), CGP-53437 from Ciba-Geigy, L-735524 from Merck and Bayer and Hearst Hoe / Bay-793, of which DM-323 is in Phase I clinical trials and L-735524 is approaching the clinical trial phase. In addition, at the moment